Indeed, drugs targeting phosphoinositide 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) have shown promising results against resistance to HER2-targeted therapies in breast cancer cell lines12. This evidence concerns the gene ERBB2 and breast carcinoma.